Drug intelligence / Profile preview

NAL1219

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

NAL1219 is a transdermal patch formulation of diclofenac sodium developed by NAL Pharmaceutical Group for the management of pain. As a nonsteroidal anti-inflammatory drug (NSAID), diclofenac acts by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, which are responsible for the production of prostaglandins that mediate inflammation and pain. The NAL1219 formulation is designed as a once-daily patch, utilizing transdermal delivery to provide sustained therapeutic levels of the drug while potentially reducing the systemic side effects, such as gastrointestinal irritation, commonly associated with oral NSAID use. The program is currently in preclinical development.

Other names: Diclofenac Sodium 1-Day PatchDiclofenac sodium

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on NAL1219.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL1219.

Explore the full profile